Related references
Note: Only part of the references are listed.Big spleens and hypersplenism: fix it or forget it?
Thomas D. Boyer et al.
LIVER INTERNATIONAL (2015)
Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats through Inhibition of mTORC1 but Not mTORC2
Weijie Wang et al.
PLOS ONE (2014)
Effect of Rapamycin on Spleen Size in Longstanding Renal Transplant Recipients
N. C. Araujo et al.
TRANSPLANTATION PROCEEDINGS (2014)
The spleen is a player in portal hypertension
Hongqun Liu et al.
EXPERIMENTAL PHYSIOLOGY (2012)
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
Eleonora Patsenker et al.
JOURNAL OF HEPATOLOGY (2011)
Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension
Marc Mejias et al.
JOURNAL OF HEPATOLOGY (2010)
Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats
Marc Mejias et al.
HEPATOLOGY (2009)
Angiogenesis in liver disease
Mercedes Fernandez et al.
JOURNAL OF HEPATOLOGY (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Mechanisms of angiogenesis
A. F. Karamysheva
BIOCHEMISTRY-MOSCOW (2008)
Mechanisms of hepatic fibrogenesis
Scott L. Friedman
GASTROENTEROLOGY (2008)
Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice
Anja M. Geerts et al.
HEPATOLOGY RESEARCH (2008)
Thrombocytopenia associated with chronic liver disease
Nezam Afdhal et al.
JOURNAL OF HEPATOLOGY (2008)
Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats
Snia Tugues et al.
HEPATOLOGY (2007)
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats
Mercedes Fernandez et al.
HEPATOLOGY (2007)
Splenic hemodynamics and decreased endothelial nitric oxide synthase in the spleen of rats with liver cirrhosis
Shohei Yamaguchi et al.
LIFE SCIENCES (2007)
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Chi Kwan Tsang et al.
DRUG DISCOVERY TODAY (2007)
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis
Markus Neef et al.
JOURNAL OF HEPATOLOGY (2006)
Complexity of the TOR signaling network
K Inoki et al.
TRENDS IN CELL BIOLOGY (2006)
Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis
SA Lakhani et al.
SCIENCE (2006)
Structure and function of the spleen
RE Mebius et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
M Fernandez et al.
JOURNAL OF HEPATOLOGY (2005)
Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis:: Analysis of the underlying mechanisms
E Biecker et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
DC Fingar et al.
ONCOGENE (2004)
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin
M Mayerhofer et al.
BLOOD (2002)
Role of spleen enlargement in cirrhosis with portal hypertension
M Bolognesi et al.
DIGESTIVE AND LIVER DISEASE (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis
M Kolb et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
NF-kappa B: a key role in inflammatory diseases
PP Tak et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Splenomegaly, hypersplenism and coagulation abnormalities in liver disease
PA McCormick et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2000)
Share Paper
